Table 2 Clinical trials of fourth-generation/next-generation and gene-edited CAR-T cell therapies around the world
Number | Disease | Binding epitope | Armor/gene-edit | Location | Start time | Study completion | Number enrolled | Status |
|---|---|---|---|---|---|---|---|---|
NCT04162119 | MM | BCMA | PD-1Fc | Sanya, Hainan, China | 2019/7/7 | 2022/10/10 | 30 | Recruiting |
NCT04109482 | BPDCN,AML,HRMDS | CD123 | Truncated EGFR | Durham, North Carolina, USA | 2020/2/25 | 2026/4/1 | 126 | Recruiting |
NCT03778346 | MM | CD138, integrin β7, CS1, CD38, and BCMA | IL7 and CCL19 | Lishui, Zhejiang, China | 2018/11/15 | 2022/12/31 | 30 | Recruiting |
NCT03929107 | B cell lymphoma | CD19 | IL-7 and CLL 19 | Hangzhou, Zhejiang, China | 2019/3/28 | 2022/4/30 | 80 | Recruiting |
NCT03258047 | B cell lymphoma | CD19 | PD1/CD28 switch-receptor | Hangzhou, Zhejiang, China | 2017/9/15 | 2019/7/30 | 60 | Active, not recruiting |
NCT03208556 | B cell lymphoma | CD19 | PD1 shRNA-expressing cassette | Beijing, China | 2017/6/21 | 2020/6/1 | 20 | Recruiting |
NCT03932955 | B cell lymphoma | CD19 | PD1/CD28 switch-receptor | Beijing, China | 2019/5/1 | 2021/5/1 | 15 | Recruiting |
NCT04163302 | B cell lymphoma | CD19 | PD-1Fc | Sanya, Hainan, China | 2019/7/7 | 2022/7/1 | 30 | Recruiting |
NCT03085173 | B-CLL | CD19 | 4–1BBL | New York, USA | 2017/3/15 | 2020/3/1 | 37 | Recruiting |
ChiCTR1900021295 | DLBCL | CD19 | Dominant negative PD1 molecule | Shanghai, China | 2018/6/1 | 2022/6/1 | 5 | Not mentioned |
NCT03602157 | HL CTCL | CD30 | CCR4 | Chapel Hill, North Carolina, USA | 2018/12/12 | 2041/9/30 | 59 | Recruiting |
NCT03182816 | Advanced solid tumor | EGFR | CTLA-4/PD-1 antibody | Ningbo, Zhejiang, China | 2017/6/7 | 2019/4/20 | 40 | Unknown |
NCT02873390 | Advanced solid tumor | EGFR | PD-1 antibody | Ningbo, Zhejiang, China | 2016/8/1 | 2018/7/1 | 20 | Unknown |
NCT03635632 | Neuroblastoma | GD2 | IL-7 receptors | Houston, Texas, USA | 2019/4/23 | 2037/12/1 | 64 | Recruiting |
NCT03721068 | Neuroblastoma | GD2 | IL-15 | Chapel Hill, North Carolina, USA | 2019/2/19 | 2039/6/19 | 18 | Recruiting |
NCT03030001 | Advanced solid tumor | Mesothelin | PD-1 antibody | Ningbo, Zhejiang, China | 2017/2/15 | 2019/2/1 | 40 | Unknown |
NCT03182803 | Advanced solid tumor | Mesothelin | CTLA-4/PD-1 antibody | Ningbo, Zhejiang, China | 2017/6/7 | 2019/4/20 | 40 | Unknown |
NCT03615313 | Advanced solid tumor | Mesothelin | PD-1 antibodies | Shanghai, China | 2018/8/6 | 2020/12/3 | 50 | Recruiting |
NCT03179007 | Advanced solid tumor | MUC1 | Anti-CTLA-4/PD-1 | Ningbo, Zhejiang, China | 2017/6/7 | 2019/4/20 | 40 | Unknown |
NCT02498912 | Advanced solid tumor | MUC16 | IL-12 | New York, USA | 2015/8/1 | 2020/8/1 | 30 | Recruiting |
NCT03932565 | Advanced solid tumor | Nectin4 | IL7 and CCL19, or IL12 | Zhejiang, China | 2019/2/13 | 2021/12/3 | 30 | Recruiting |
NCT04381741 | DLBCL | CD19 | IL7 and CCL19 | Zhejiang, China | 2020/9/1 | 2023/9/1 | 24 | Recruiting |
NCT03721068 | Neuroblastoma | GD2 | IL-15 | North Carolina, USA | 2019/2/19 | 2039/6/19 | 18 | Recruiting |
NCT04093648 | Hepatoblastoma | Glypican 3 | IL21 and IL15 | United States | 2020/1/1 | 2038/1/1 | 60 | Not yet recruiting |
NCT04185038 | Central nervous system tumor | B7H3 | Truncated EGFR | Washington, USA | 2019/12/11 | 2041/5/1 | 70 | Recruiting |
NCT03208556 | B cell lymphoma | CD19 | PD1 shRNA-expressing cassette | Beijing, China | 2016/7/1 | 2019/7/1 | 20 | Recruiting |
NCT03198546 | Hepatocellular carcinoma | GPC3 | Soluble TGFβ | Guangdong, China | 2017/7/1 | 2022/8/1 | 30 | Recruiting |
NCT03706326 | Advanced esophageal cancer | MUC1 | PD-1 Knockout | Guangdong, China | 2018/9/28 | 2021/9/28 | 20 | Recruiting |
NCT03525782 | Non-small cell lung cancer | MUC1 | PD-1 Knockout | Guangdong, China | 2018/2/1 | 2022/1/31 | 60 | Recruiting |
NCT03545815 | Solid tumor | Mesothelin | PD-1 Knockout | Beijing, China | 2018/6/1 | 2020/6/30 | 10 | Recruiting |
NCT03298828 | B-ALL and Buekitt lynphoma | CD19 | PD-1 Knockout | Chongqing, china | 2017/11/1 | 2022/10/1 | 30 | Not yet recruiting |